<DOC>
	<DOCNO>NCT03054181</DOCNO>
	<brief_summary>Long-term observational study utilisation outcome HyQvia ( product consist recombinant human hyaluronidase human normal immunoglobulin 10 % solution ) everyday clinical practice condition .</brief_summary>
	<brief_title>Facilitated Immunoglobulin Administration Registry Outcomes Study ( FIGARO )</brief_title>
	<detailed_description>Recombinant hyaluronidase establish therapeutic principle facilitate infusion large volume fluid subcutaneously ( e.g . Ringer solution antibody IG , rituximab , trastuzumab ) . HyQvia product consist recombinant human hyaluronidase ( rHuPH20 , HylenexÂ® ) , human normal immunoglobulin ( IG ) . The subcutaneous ( SC ) IG 10 % solution prepared human plasma consist least 98 % immunoglobulin G , contain broad spectrum antibody . The two component package together dual vial unit : IG provide therapeutic effect recombinant human hyaluronidase facilitate dispersion , alters kinetics absorption increase bioavailability IG . HyQvia market European Union ( EU ) since July 2013 USA since September 2014 . In EU , HyQvia indicate replacement therapy patient age group primary immunodeficiency syndrome ( PID ) , myeloma chronic lymphocytic leukaemia severe secondary hypogammaglobulinaemia recurrent infection ( secondary immunodeficiency syndrome , SID ) , well hypogammaglobulinaemia pre- post-allogeneic hematopoietic stem cell transplantation . HyQvia investigate one pivotal study last year , involve 89 patient PID already treatment human normal IG least three month . The number acute serious bacterial infection ( SBI ) main efficacy outcomes 0.025 per year . This FDA predefined number need show efficacy ( SBI rate &lt; 1.0 per subject per year 0.01 level significance ) , similar see licensed human normal IG product . In pivotal study extension , 188 patient year HyQvia treatment document . HyQvia efficacious , safe , bioequivalent intravenous IG administration interval , cause few systemic reaction . Tolerability good despite high infusion volume rate . There preclinical data suggest increase risk mutagenicity , teratogenicity , fertility neuronal development . The current comprehensive data real-life utilisation outcomes various IgG preparation available German SIGNS registry . This registry confirm effectiveness IgG substitution treatment term reduction infection ( PID SID ) , well stabilization improvement clinical condition neurological autoimmune disease . In cohort 24 PID SID patient HyQvia German SIGNS study , preparation well tolerated treatment satisfaction high . In country , data utilisation outcomes HyQvia clinical practice condition sparse completely miss . The present study aim fill gap provide detailed complete description utilisation everyday clinical practice condition .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patient received/will receive least 1 HyQvia infusion PID SID Patient indication chronic immunoglobulin treatment Patient likely available longterm documentation Patient provide informed consent documentation No explicit exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Observational</keyword>
	<keyword>Infection</keyword>
	<keyword>Utilisation</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Infusion</keyword>
	<keyword>chronic</keyword>
</DOC>